DENVER--(BUSINESS WIRE)--Lifeline Therapeutics, Inc. (OTCBB:LFLT), maker of Protandim®, announced today that it will recognize previously deferred revenue and costs related to its retail partner, GNC. As previously disclosed, revenue under this contract had been deferred due to minimal sales history. Following a full year of sales under the contract and growing retail presence on the part of Protandim®, and after discussion with its independent outside auditors, Lifeline Therapeutics, Inc. will begin to recognize some of the previously deferred revenue and costs as well as continuing revenue and costs associated with the GNC agreement. The revenue and costs associated with the contract will be recognized based on GNC customer sales, and will be fully disclosed in the Company’s Form 10-QSB for the first quarter of fiscal year 2007 due on November 14, 2006.
